- Home
- CRVS vs PVLA Comparison
CRVS vs PVLA Comparison
Compare CRVS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- PVLA
- Stock Information
- Founded
- CRVS 2014
- PVLA 2015
- Country
- CRVS United States
- PVLA United States
- Employees
- CRVS N/A
- PVLA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- PVLA Health Care
- Exchange
- CRVS Nasdaq
- PVLA Nasdaq
- Market Cap
- CRVS 305.4M
- PVLA 285.2M
- IPO Year
- CRVS 2016
- PVLA N/A
- Fundamental
- Price
- CRVS $5.75
- PVLA $54.15
- Analyst Decision
- CRVS Strong Buy
- PVLA Strong Buy
- Analyst Count
- CRVS 4
- PVLA 11
- Target Price
- CRVS $15.00
- PVLA $56.64
- AVG Volume (30 Days)
- CRVS 518.7K
- PVLA 133.4K
- Earning Date
- CRVS 08-07-2025
- PVLA 08-14-2025
- Dividend Yield
- CRVS N/A
- PVLA N/A
- EPS Growth
- CRVS N/A
- PVLA N/A
- EPS
- CRVS N/A
- PVLA N/A
- Revenue
- CRVS N/A
- PVLA N/A
- Revenue This Year
- CRVS N/A
- PVLA N/A
- Revenue Next Year
- CRVS N/A
- PVLA N/A
- P/E Ratio
- CRVS N/A
- PVLA N/A
- Revenue Growth
- CRVS N/A
- PVLA N/A
- 52 Week Low
- CRVS $2.54
- PVLA $11.17
- 52 Week High
- CRVS $10.00
- PVLA $57.19
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- PVLA 67.56
- Support Level
- CRVS $5.28
- PVLA $49.13
- Resistance Level
- CRVS $5.64
- PVLA $57.19
- Average True Range (ATR)
- CRVS 0.30
- PVLA 4.30
- MACD
- CRVS 0.03
- PVLA 0.15
- Stochastic Oscillator
- CRVS 77.70
- PVLA 81.32
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.